Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 10,370 shares, a growth of 203.9% from the July 15th total of 3,412 shares. Based on an average trading volume of 3,070 shares, the days-to-cover ratio is presently 3.4 days.
Oculis Price Performance
Shares of Oculis stock remained flat at $5.00 during trading on Thursday. 277 shares of the company traded hands, compared to its average volume of 5,654. The firm’s 50-day simple moving average is $4.44 and its 200-day simple moving average is $12.13. Oculis has a 12-month low of $3.63 and a 12-month high of $22.64.
About Oculis
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
See Also
- Five stocks we like better than Oculis
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
